Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)-Reference-Cited by-同舟云学术

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

Published:2017-12-08 Issue:24 Volume:60 Page:9960-9973
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Tully David C.¹²^ORCID,Rucker Paul V.¹,Chianelli Donatella¹,Williams Jennifer¹,Vidal Agnès¹,Alper Phil B.¹^ORCID,Mutnick Daniel¹,Bursulaya Badry¹,Schmeits James¹,Wu Xiangdong¹,Bao Dingjiu¹,Zoll Jocelyn¹,Kim Young¹,Groessl Todd¹,McNamara Peter¹,Seidel H. Martin¹,Molteni Valentina¹,Liu Bo¹,Phimister Andrew²,Joseph Sean B.¹,Laffitte Bryan¹

Affiliation:

1. Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States

2. Novartis Institutes for Biomedical Research, Emeryville, California 94608, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00907

Reference33 articles.

1. Bile acids: regulation of synthesis

2. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR